aged 70-80 or younger (but with poor ECOG PS) received a CBDCA + VP16 treatment, at a 4-week interval as follows: cycle 1: CBDCA = AUC 4; VP16 = 50 mg b.i.d. orally d 1-14); cycle 2: CBDCA = AUC 5; VP16 = 50 mg b.i.d. orally d 1-14; cycle 3: CBDCA = AUC ...
Hexamethylmelamine (HMM) and oral etoposide (VP-16) have shown to be active against platinum-resistant epithelial ovarian cancer. On this basis a three-drug regimen including carboplatin (CBDCA) plus HMM and oral VP-16 was tested in previously untreated ovarian cancer patients with tumor size &...
目的:研究化学抗癌药物联合治疗小细胞肺癌的效果.方法:应用TAX,CBDCA与VP16联合治疗30例晚期小细胞肺癌.结果:CR 2例,PR 19例,总有效率达70%(21/30),且毒副反应较轻,无Ⅲ,Ⅳ级发生.结论:TAX,CBDCA与VP16三药联用治疗小细胞性肺癌临床疗效较显著.关键...
Lung Cancer Volume 11, Supplement 1, June 1994, Pages 101Abstract Therapy Chemotherapy/Small cellDose escalation study of carboplatin (CBDCA) and etoposide (VP-16) with G-CSF in small cell lung cancer (SCLC) : N. Katakami∗, M. Okazaki∗, Y. Ariyoshi, H. Ikegami, K. Furuse, M. ...
243 A phase II study of the recombinant human interleukin 3 (IL-3) following carboplatin (CBDCA) and etoposide (VP-16) chemotherapy in patients with ... S Kudo,N Kurihara,K Furuse,... 被引量: 0发表: 1995年 Abrogation of the hematological and biological activities of the interleukin-3/gr...
--> Abstract: The purpose of this study was to determine the efficacy of salvage chemotherapy with, P‐IMVP‐16/CBDCA, consisting of carboplatin (CBDCA), etoposide (VP‐16), ifosfamide (IFM), and methotrexate (MTX), for patients with aggressive non‐Hodgkin's lymphoma (NHL) who had ...
The disposition of the cisplatin analogue carboplatin was studied in seven patients with small cell lung cancer. Carboplatin 100 mg/m 2 was administered without hydration by a 1-h infusion with VP16-213 120 mg/m 2 on days 1, 2 and 3 of each course. Plasma and urine collections were ...
Carboplatin (CBDCA) plus etoposide (VP-16) in non small cell lung cancer (NSCLC) treatment - European Journal of Cancerdoi:10.1016/0959-8049(93)91532-PBernardo, G.Bernardo, A.Plastina, M.Strada, M.R.Brunetti, G.Pozzi, U.Rossi, A....
243 A phase II study of the recombinant human interleukin 3 (IL-3) following carboplatin (CBDCA) and etoposide (VP-16) chemotherapy in patients with small cell lung cancer (SCLC)doi:10.1016/0959-8049(95)95501-VTo evaluate the safety and the efficacy of IL-3 (Sandoz), SCLC patients (pts...